Company

Oxford Cannabinoid Technologies Ltd.

Oxford-based developer of pharmaceuticals that target the endocannabinoid system for chronic pain and oncology symptoms.

About

Oxford Cannabinoid Technologies Ltd. was founded in 2017 in Oxford, UK, by Tarek Tabsh. It develops pharmaceuticals that target the endocannabinoid system, aiming to offer non-addictive alternatives for chronic pain and oncology-related symptoms. Clarissa Sowemimo-Coker is CEO. On June 28, 2018 the company raised GBP 7.6 million in Series A financing led by Casa Verde Capital. Stage: Series A.

2Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in